Dicot Pharma AB publishes prospectus in connection with the upcoming rights issue
Uppsala, Sweden, August 14, 2024. The Board of Directors of Dicot Pharma AB today publishes an EU growth prospectus (the "Prospectus") in relation to the rights issue of units consisting of shares and warrants of series TO6 resolved by the Board of Directors on August 7, 2024 (the "Rights Issue"). The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH